Burger HG, Fuller PJ. The inhibin/activin family and ovarian cancer. Trends Endocrinol Metab 1996;7:197–202.
Lappöhn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruijn H. Inhibin as a marker for granulosa-cell tumors. N Engl J Med 1989;321:790–3.
Kauppila A, Bangah M, Burger HG, Martikainen H. GnRH agonist therapy in advanced/recurrent granulosa cell tumors: further evidence of a role of inhibin monitoring response to treament. Gynecol Endocrinol 1992;6:271–4.
Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, et al. Inhibin: a serum marker for mucinous ovarian cancers. N Engl J Med 1993;329:1539–42.
Burger HG. Clincial review—Clinical utility of inhibin measurements. J Clin Endocrinol Metab 1993;76:1391–6.
Jobling T, Mamers P, Healy DL, MacLachlan V, Burger HG, Quinn M, et al. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 1994;55:285–9.
Groome NP, Illingworth PG, O’Brien M, Cooke I, Ganesan TS, Baird DT, et al. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol 1994;40:717–23.
Groome NP, Illingworth PJ, O’Brien M, Roger PAL, Rodger FE, Mather JP, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401–5.
Burger HG, Robertson DM, Cahir N, Mamers P, Healy DL, Jobling T, et al. Characterisation of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin Endocrinol 1996;44:413–8.
Cooke I, O’Brien M, Charnock FM, Groome NP, Ganesan TS. Inhibin as a marker for ovarian cancer. Br J Cancer 1995;71:1046–50.
Robertson DM, Burger HG, Sullivan J, Cahir N, Groome N, Poncelet E, et al. Biological and immunological characterisation of inhibin forms in human plasma. J Clin Endocrinol Metab 1996;81:669–76.
Sluijmer AV, Heineman MJ, Evers JLH, de Jong FH. Peripheral vein, ovarian vein and ovarian tissue levels of inhibin in a postmenopausal patient with a granulosa cell tumour. Acta Endocrinol (Copenh) 1993;129:311–14.
Gurusinghe CJ, Healy DL, Jobling T, Mamers P, Burger HG. Inhibin and activin are demonstrable by immunohistochemisty in ovarian tumor tissue. Gynecol Oncol 1995;57:27–32.
Matzuk MM, Finegold MK, Su JG, Hsueh AJ, Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature (Lond) 1992;360:313–9.
Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM. Activin signalling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient, mice. Mol Endocrinol 1996;10:534–43.
Shen Y, Mamers P, Jobling T, Burger HG, Fuller PJ. Absence of the previously reported G-protein oncogence (gip21in ovarian granulosa cell tumors. J Clin Endocrinol Metab 1996;81:4159–61.
Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655–9.